Clinical Scorecard: Real-World Eylea HD Data Presented at ARVO
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) |
| Key Mechanisms | Aflibercept 8 mg (Eylea HD) reduces injection frequency while maintaining or improving vision. |
| Target Population | Patients with nAMD and DME, including treatment-naïve and previously treated individuals. |
| Care Setting | Clinical practice, based on electronic health record data. |
Key Highlights
- Nearly 40,000 patients analyzed from the IRIS Registry and Vestrum Health Retina Databases.
- Switching to Eylea HD extended injection intervals by 2 to 3 weeks in previously treated patients.
- Early visual improvements observed in treatment-naïve patients with poor baseline vision.
- Post-loading phase injection intervals averaged 63 to 69 days for treatment-naïve patients.
- No new safety signals identified; common adverse events included cataract and increased intraocular pressure.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and retinal imaging for nAMD and DME.
Management
- Consider Eylea HD for patients requiring reduced injection frequency.
Monitoring & Follow-up
- Regularly monitor visual acuity and intraocular pressure.
Risks
- Monitor for cataract, increased intraocular pressure, conjunctival hemorrhage, and eye discomfort.
Patient & Prescribing Data
Patients with nAMD and DME, both treatment-naïve and previously treated.
Switching to Eylea HD may allow for longer intervals between injections without compromising vision.
Clinical Best Practices
- Evaluate baseline vision to tailor treatment plans.
- Utilize electronic health records for tracking patient outcomes.
- Educate patients on potential adverse events and monitoring needs.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.